Cross-sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program
| Autor: | Jothydev Kesavadev, Wayne Huey-Herng Sheu, Andrea O.Y. Luk, Thy Khue Nguyen, Chiu Chi Tsang, Hari Janakiraman, Sosale Ramachandra Aravind, Monojitketan Mukhopadhyay, Amy W C Fu, Quang Khanh Tran, Risa Ozaki, Roberto Mirasol, Linsey Gani, Sanjeev Phatak, Leorino Sobrepena, Sujeet Jha, Juliana C.N. Chan, Christine M. L. Kwan, Yoon Kun Ho, Wing-Yee So, Weiping Jia, Weinan Yu, Kanakatte Mylariah Prasanna Kumar, Eric S.H. Lau |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Asia Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Type 2 diabetes Hypoglycemia 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Diabetes mellitus Internal Medicine medicine Humans Hypoglycemic Agents Insulin 030212 general & internal medicine Biosimilar Pharmaceuticals Glycemic business.industry Biosimilar General Medicine Articles Middle Aged medicine.disease Cross-Sectional Studies Diabetes Mellitus Type 1 Treatment Outcome Clinical Science and Care chemistry Diabetes Mellitus Type 2 Female Original Article Glycated hemoglobin business Body mass index |
| Zdroj: | Journal of Diabetes Investigation |
| ISSN: | 2040-1124 |
| Popis: | Aims/Introduction Biosimilar insulin can reduce treatment costs, although the extent of its use is largely unknown. We examined biosimilar insulin use and its associations with the quality of glycemic control using the Joint Asia Diabetes Evaluation register. Materials and Methods We carried out a cross‐sectional analysis in 81,531 patients with type 1 and type 2 diabetes enrolled into the Joint Asia Diabetes Evaluation Program from 2007 to 2014. All insulin related terms are extracted from the Joint Asia Diabetes Evaluation portal, and compared clinical profiles between biosimilar and originator insulin users. Multivariate analysis was performed to assess the association of biosimilar insulin compared with originator insulin with dosage, glycated hemoglobin and hypoglycemia events. Results Amongst 81,531 patients, 20.5% (n = 16,738) were insulin‐treated. In four countries with high use of biosimilar insulin, 4.7% (n = 719) of insulin users (n = 10,197) were treated with biosimilar insulin (India n = 507, 70.3%; the Philippines n = 90, 12.5%; China n = 62, 8.6%; Vietnam n = 60, 8.3%). Biosimilar insulin users were younger and had higher body mass index, glycated hemoglobin, insulin dosage and more frequent hypoglycemia than originator insulin users. These associations were non‐significant after adjustment for confounders. Only age, college education, diabetes education, lipid control, physical activity and history of cardiovascular complications were independently associated with these quality measures. Conclusions Biosimilar insulin use is not uncommon in Asia. Data exclusion due to incomplete capturing of brand names suggests possibly higher use. The multiple determinants of the quality of glycemic control call for establishment of prospective cohorts and diabetes registers to monitor the safety and efficacy of different brands of biosimilar insulin and their impacts on clinical outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text